Showing posts with label Clinical Trial. Show all posts
Showing posts with label Clinical Trial. Show all posts

Saturday, October 17, 2020

World's first transplant of iPS visual cells for retinal disease

(c) Kyodo News
The world's first clinical trial of a transplant of visual cells derived from induced pluripotent stem cells, or iPS cells, to treat a patient with pigmentary retinal degeneration was performed without any complications in Japan.

Tuesday, December 18, 2018

Injection Improves Vision in a Form of Childhood Blindness

(c) NIH
A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute  in the Perelman School of Medicine at the University of Pennsylvania.

Monday, October 9, 2017

FDA to soon decide approval for Spark Therapeutics' gene therapy for Leber Congenital Amaurosis

In the next few days, FDA panel will consider whether to advice approval for gene therapy for Leber's Congenital Amaurosis (LCA), which has been extensively tested in clinical trials by Spark Therapeutics.

Tuesday, September 29, 2015

First patient receives potential new treatment for wet age-related macular degeneration (AMD)

A pioneering trial of a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) has commenced at Moorfields Eye Hospital following a successful operation on a patient.

Monday, August 24, 2015

RetroSense Therapeutics Gets Approval for Clinical Trials in Retinitis Pigmentosa

(c) nature.com
RetroSense Therapeutics’ Investigational New Drug (IND) application for gene therapy based clinical trial for their product RST-001 has received clearance from the US Food and Drug Administration. RetroSense is developing RST-001 for the treatment of retinitis pigmentosa, a genetic condition that leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina that sense light), resulting in severe vision loss and blindness. With its IND now in effect, RetroSense expects to initiate a Phase I/II clinical trial by year-end in order to evaluate the safety and, potentially, efficacy of RST-001.

Wednesday, August 12, 2015

UCI-led team begins first clinical trial of stem cell-based retinitis pigmentosa treatment

Participants are being enrolled in the first clinical trial that tests the use of retinal progenitor cells to treat retinitis pigmentosa. The product of stem cell research at UCI’s Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center, these retinal progenitors are similar to stem cells in terms of potential regenerative properties, but they’re specific to the retina.